Short and oral antimicrobial therapy for diabetic foot infection: a narrative review of current knowledge.

IF 1.8 Q3 INFECTIOUS DISEASES Journal of Bone and Joint Infection Pub Date : 2022-01-01 DOI:10.5194/jbji-7-61-2022
Steven M Maurer, Zehra S Hepp, Shawna McCallin, Felix W A Waibel, Federico C Romero, Yılmaz Zorman, Benjamin A Lipsky, İlker Uçkay
{"title":"Short and oral antimicrobial therapy for diabetic foot infection: a narrative review of current knowledge.","authors":"Steven M Maurer,&nbsp;Zehra S Hepp,&nbsp;Shawna McCallin,&nbsp;Felix W A Waibel,&nbsp;Federico C Romero,&nbsp;Yılmaz Zorman,&nbsp;Benjamin A Lipsky,&nbsp;İlker Uçkay","doi":"10.5194/jbji-7-61-2022","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetic foot infection is a frequent complication in long-standing diabetes mellitus. For antimicrobial therapy of this infection, both the optimal duration and the route of administration are often based more on expert opinion than on published evidence. We reviewed the scientific literature, specifically seeking prospective trials, and aimed at addressing two clinical issues: (1) shortening the currently recommended antibiotic duration and (2) using oral (rather than parenteral) therapy, especially after the patient has undergone debridement and revascularization. We also reviewed some older key articles that are critical to our understanding of the treatment of these infections, particularly with respect to diabetic foot osteomyelitis. Our conclusion is that the maximum duration of antibiotic therapy for osteomyelitis should be no more than to 4-6 weeks and might even be shorter in selected cases. In the future, in addition to conducting randomized trials and propagating national and international guidance, we should also explore innovative strategies, such as intraosseous antibiotic agents and bacteriophages.</p>","PeriodicalId":15271,"journal":{"name":"Journal of Bone and Joint Infection","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990364/pdf/","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Joint Infection","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5194/jbji-7-61-2022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 6

Abstract

Diabetic foot infection is a frequent complication in long-standing diabetes mellitus. For antimicrobial therapy of this infection, both the optimal duration and the route of administration are often based more on expert opinion than on published evidence. We reviewed the scientific literature, specifically seeking prospective trials, and aimed at addressing two clinical issues: (1) shortening the currently recommended antibiotic duration and (2) using oral (rather than parenteral) therapy, especially after the patient has undergone debridement and revascularization. We also reviewed some older key articles that are critical to our understanding of the treatment of these infections, particularly with respect to diabetic foot osteomyelitis. Our conclusion is that the maximum duration of antibiotic therapy for osteomyelitis should be no more than to 4-6 weeks and might even be shorter in selected cases. In the future, in addition to conducting randomized trials and propagating national and international guidance, we should also explore innovative strategies, such as intraosseous antibiotic agents and bacteriophages.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
短期和口服抗菌药物治疗糖尿病足感染:当前知识的叙述回顾。
糖尿病足感染是长期糖尿病患者的常见并发症。对于这种感染的抗菌治疗,最佳持续时间和给药途径往往更多地基于专家意见,而不是公开的证据。我们回顾了科学文献,特别寻找前瞻性试验,旨在解决两个临床问题:(1)缩短目前推荐的抗生素持续时间;(2)使用口服(而不是肠外)治疗,特别是在患者进行清创和血供重建术后。我们也回顾了一些旧的关键文章,这些文章对我们理解这些感染的治疗至关重要,特别是关于糖尿病足骨髓炎。我们的结论是,抗生素治疗骨髓炎的最长持续时间不应超过4-6周,在某些情况下甚至可以更短。未来,除了开展随机试验和宣传国家和国际指导外,我们还应该探索创新策略,如骨内抗生素和噬菌体。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
29
审稿时长
12 weeks
期刊最新文献
Musculoskeletal manifestations of lower-extremity coccidioidomycosis: a case series Emergence of rifampicin-resistant staphylococci on the skin and nose of rifampicin-treated patients with an orthopaedic-device-related infection What is the agreement between principles and practice of antibiotic stewardship in the management of diabetic foot infection: an in-hospital quality control study. It is time for a unified definition of native vertebral osteomyelitis: a framework proposal. Ureaplasma urealyticum osteomyelitis of the greater trochanter in a patient with multiple sclerosis using ocrelizumab – a case report
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1